Shamburg News · 8-K filed Nov 12, 2026, 7:33 AM EST
Altimmune Reports Third Quarter 2026 Net Loss of $31.6 Million, Provides Pipeline Update
ALT · Altimmune, Inc.
- Earnings
- Materiality: high
Altimmune, Inc. reported a net loss of $31.6 million, or $0.15 per share, for the three months ended September 30, 2026, compared with a net loss of $19.0 million, or $0.21 per share, a year earlier. Research and development expenses rose to $27.0 million from $15.0 million, driven primarily by the PERFORMA Phase 3 MASH trial and the RESTORE Phase 2 ALD trial. The company reported $480 million in cash, cash equivalents and investments as of September 30, 2026, and reported no revenue for the quarter.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001326190-26-000067.
Written from the filing by Shamburg Markets. Figures are as reported by the company.